@article{PCM4665,
author = {Luis Alvarez-Vallina},
title = {4-1BB-mediated cancer immunotherapy: ‘mission impossible’ for non-engineered IgGs?},
journal = {Precision Cancer Medicine},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {Increasing tumor-specific immune responses with immunostimulatory monoclonal antibodies (mAbs) is a promising strategy in cancer therapy. Antagonistic mAbs blocking signaling through inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) have been shown to induce sustained anti-tumor responses in many cancers across various histologies, and agonistic mAbs targeting activator receptors are undergoing clinical trials (1).},
issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/4665}
}